Real-world survival in patients with mixed phenotype ATTR-CM treated with tafamidis

In this video, Jonas Wixner, MD, PhD, Umeå University, Umeå, Sweden, discusses the survival outcomes in a real-world cohort of patients with mixed phenotype transthyretin amyloid cardiomyopathy (ATTR-CM) treated with tafamidis. Findings show that tafamidis improves survival in both wild-type and variant patients. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.